No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
58 |
4. Check minimum number of eventsNone |
58 |
5. Include endpointsNone |
58 |
6. Filter based on genotype QC (FinnGen only) |
51 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Autoimmune polyglandular failure
based on the number of shared cases.
Similar with more cases:
- Polyglandular dysfunction
- Disorders of other endocrine glands
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Endocrine, nutritional and metabolic diseases
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 302 | 189 | 110 |
| Only index persons | 247 | 161 | 86 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.01 | 0.00 |
| Only index persons | 0.01 | 0.01 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 33.80 | 36.67 | 28.51 |
| Only index persons | 31.59 | 35.00 | 25.22 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 51 | 30 | 21 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 26.66 | 34.27 | 15.79 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 52
- Matched controls
- 520
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB09
ATC
hydrocortisone; systemic
311.9
37.4
34
*
H02AA02
ATC
fludrocortisone; oral
+∞
36.9
31
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
35.5
30
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
30.1
26
*
E31.00
ICD-10 Finland
APECED syndrome
+∞
30.1
26
*
H03AA01
ATC
levothyroxine sodium; systemic
13.0
20.0
34
66
E31.08
ICD-10 Finland
Autoimmune polyglandular failure
+∞
18.9
17
*
106
Kela drug reimbursment
Hypoparathyroidism
+∞
17.7
16
*
A12AA04
ATC
calcium carbonate; oral
245.7
17.7
17
*
A11CC03
ATC
alfacalcidol; systemic
89.2
17.0
18
*
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
20.1
15.4
24
21
A10AE05
ATC
insulin detemir; parenteral
24.1
14.7
21
14
A11CC02
ATC
dihydrotachysterol; oral
+∞
14.2
13
*
T89
ICPC
Diabetes insulin dependent
19.1
14.1
22
19
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
169.2
13.1
13
*
E83.51
ICD-10 Finland
Hypocalcemia
+∞
13.0
12
*
A10AB04
ATC
insulin lispro; parenteral
20.5
12.7
19
14
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
7.4
12.0
29
76
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
152.4
12.0
12
*
A10AC01
ATC
insulin (human); parenteral
13.9
11.8
21
24
215
Kela drug reimbursment
Diabetes, non-insulin-treated
7.3
11.7
27
67
103
Kela drug reimbursment
Diabetes, insulin-treated
7.2
11.5
27
68
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
56.3
11.5
13
*
A10AE04
ATC
insulin glargine; parenteral
12.3
11.5
22
29
A10AB05
ATC
insulin aspart; parenteral
12.7
11.3
21
26
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
7.0
10.9
25
61
121
Kela drug reimbursment
Severe hypofunction of sexual glands
42.2
10.9
13
*
107
Kela drug reimbursment
Pernicious anaemia
+∞
10.8
10
*
2581B
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[AUTOIMMUNE-POLYENDOCRINOPATHY-CANDIDOSIS-ECTOD DYST]
+∞
10.8
10
*
A07AA02
ATC
nystatin; oral
18.6
10.5
16
12
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
15.9
9.9
16
14
SPAT1262
SPAT
Handing over of treatment supplies
7.1
9.7
19
39
E31.0
ICD-10 Finland
Autoimmune polyglandular failure
+∞
9.7
9
*
2581A
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[SYNDROMA SCHMIDT]
+∞
9.7
9
*
25510
ICD-8 Finland
Diseases of adrenal glands, Adrenal cortical hypofunction
+∞
9.7
9
*
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
24.1
9.5
13
7
B03BA03
ATC
hydroxocobalamin; parenteral
30.4
9.4
12
5
A10AB01
ATC
insulin (human); parenteral
13.0
9.1
16
17
A01AB09
ATC
miconazole; local oral
13.0
9.1
16
17
WZC00
NOMESCO Finland
Treatment plan or consultation
6.0
9.1
35
133
H04AA01
ATC
glucagon; nasal, parenteral
14.5
9.0
15
14
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.6
8.8
29
96
104
Kela drug reimbursment
Thyroid insufficiency
13.5
8.7
15
15
B37.08
ICD-10 Finland
Other candidal stomatitis
106.7
8.7
9
*
E31.01
ICD-10 Finland
Schmidt's syndrome
+∞
8.6
8
*
A12AA06
ATC
calcium lactate gluconate; oral
+∞
8.6
8
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
8.6
8
*
A01AB04
ATC
amphotericin B; local oral
21.7
8.5
12
7
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
12.6
8.5
15
16
TPH04
NOMESCO Finland
Cathetrisation of vein
5.9
8.1
19
46
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
53.3
8.0
9
*
E16.2
ICD-10 Finland
Hypoglycaemia, unspecified
53.3
8.0
9
*
E83.50
ICD-10 Finland
Hypercalcemia
53.3
8.0
9
*
SBA00
NOMESCO Finland
Microbiological examinations
30.2
7.9
10
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.5
7.9
21
57
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
16.8
7.8
12
9
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
16.8
7.8
12
9
WX002
NOMESCO Finland
Sedation and analgesia
9.5
7.8
16
23
E87.6
ICD-10 Finland
Hypokalaemia
19.4
7.6
11
7
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
12.9
7.6
13
13
J02AB02
ATC
ketoconazole; oral
24.2
7.5
10
5
XCK10
NOMESCO Finland
Photography of fundus of eye
9.1
7.2
15
22
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
11.1
7.1
13
15
K29.4
ICD-10 Finland
Chronic atrophic gastritis
46.2
7.0
8
*
H3600, E103,
ICD-10 Finland
26.6
6.9
9
*
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
4.6
6.9
31
126
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
13.5
6.7
11
10
E03.89
ICD-10 Finland
Other specified hypothyroidism
21.3
6.5
9
5
25810
ICD-8 Finland
Polyglandular dysfunction and other diseases of endocrine glands, Polyglandular dysfunction
+∞
6.4
6
*
25219
ICD-8 Finland
Diseases of parathyroid gland, Hypoparathyreoidismus alius sive NUD
+∞
6.4
6
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
6.4
6
*
E20.8
ICD-10 Finland
Other hypoparathyroidism
+∞
6.4
6
*
H01AC01
ATC
somatropin; parenteral
+∞
6.4
6
*
A10AE06
ATC
insulin degludec; parenteral
11.3
6.1
11
12
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
8.3
6.0
13
20
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
32
50
15.04
22.73
18.0
7.5
1.24
1.13
mmol/l
0.88
32
42
34
74
11.38
17.87
13.0
4.4
0.77
0.83
mmol/l
2.92
34
69
22
46
7.56
11.23
10.7
12.5
103.50
104.67
mmol/l
0.45
22
46
21
30
10.97
10.43
9.6
14.1
26.14
24.48
mmol/l
0.53
21
30
41
179
7.10
9.05
42.6
9.5
1.15
1.21
mmol/l
2.89
41
166
19
29
9.67
8.98
8.2
10.1
5.92
5.71
kpa
0.33
19
29
38
167
5.74
7.98
5.0
1.8
102.43
96.55
pmol/l
0.34
27
80
16
23
9.53
7.75
5.1
9.4
25.62
24.63
mmol/l
0.44
16
23
33
138
4.81
7.14
8.2
3.5
2.26
2.35
mmol/l
1.71
33
126
22
68
4.87
6.98
3.6
1.6
—
—
—
0
0
32
136
4.52
6.66
2.3
1.5
0.65
1.12
u/ml
0.56
11
34
9
5
21.28
6.52
2.7
2.8
—
—
—
0
0
9
6
17.72
6.15
2.8
2.5
10.22
8.33
%
—
9
6
43
249
5.19
6.05
15.0
7.7
8.85
6.47
mmol/l
3.99
43
234
9
7
15.16
5.82
4.2
1.7
16.40
16.61
%
—
9
7
30
139
3.74
5.18
8.9
2.6
—
—
—
0
0
14
31
5.78
5.03
13.1
3.1
5.29
5.12
kpa
0.31
14
31
15
38
5.12
4.81
1.4
1.3
406.60
62.87
u/ml
—
5
19
8
9
10.23
4.45
8.4
8.6
24.05
23.26
mmol/l
—
8
9
9
13
8.10
4.37
3.0
1.5
23.68
25.88
mmol/l
—
9
13
8
10
9.20
4.23
3.5
1.3
—
—
—
0
0
15
49
3.90
4.21
3.0
1.5
—
—
—
0
0
8
11
8.35
4.02
12.0
4.3
64.35
63.24
%
—
8
11
8
11
8.35
4.02
3.5
1.2
—
—
—
0
0
11
25
5.29
3.89
10.5
15.0
94.64
92.58
%
0.44
11
25
6
5
13.30
3.86
1.8
2.8
—
—
—
0
0
8
12
7.64
3.83
3.5
1.3
—
—
—
0
0
8
13
7.04
3.65
3.5
1.2
—
—
—
0
0
14
48
3.62
3.63
3.0
1.6
—
—
—
0
0
6
6
11.07
3.59
4.8
1.5
—
—
—
0
0
29
158
2.89
3.44
5.0
3.2
19.67
20.27
ng/l
0.04
21
84
12
36
4.02
3.29
4.5
3.2
—
—
—
0
0
9
20
5.21
3.29
1.9
1.8
—
—
—
0
0
23
113
2.86
3.27
3.0
1.7
0.67
1.56
mg/l
0.76
18
89
12
37
3.90
3.20
13.3
24.6
117.58
125.95
g/l
0.98
12
37
10
26
4.50
3.18
11.5
14.4
0.53
0.72
%
—
10
26
7
12
6.55
3.13
1.6
1.0
—
—
—
0
0
29
164
2.74
3.12
3.4
3.3
43.03
31.36
u/l
0.93
29
157
10
27
4.33
3.07
11.5
14.0
1.50
1.66
%
—
10
27
26
140
2.71
3.07
6.9
3.5
0.00
0.00
estimate
-0.00
16
50
8
17
5.35
3.05
7.3
10.9
1.75
1.43
%
—
8
17
7
13
6.03
2.98
2.0
1.2
1.31
0.24
ug/l
—
7
13
6
10
6.61
2.78
4.5
1.3
—
—
—
0
0
7
15
5.21
2.70
16.3
3.0
11.59
8.71
kpa
—
7
15
6
11
6.00
2.62
4.7
1.4
—
—
—
0
0
5
7
7.74
2.60
1.0
1.0
—
—
—
0
0
7
16
4.88
2.57
2.3
1.5
—
—
—
0
0
6
12
5.49
2.47
2.3
2.4
191.67
143.58
ng/l
—
6
12
5
8
6.77
2.42
1.4
1.0
—
—
—
0
0
10
35
3.29
2.36
2.1
2.6
214.70
240.43
u/l
—
10
35
7
19
4.09
2.24
20.7
3.9
25.49
25.56
mmol/l
—
7
19
8
25
3.59
2.20
18.4
23.4
24.38
24.84
mmol/l
—
8
25
5
12
4.48
1.87
1.4
1.2
—
—
—
0
0
5
12
4.48
1.87
14.0
1.8
4.22
3.85
mmol/l
—
5
12
6
19
3.43
1.71
4.3
1.7
86.83
89.47
%
—
6
19
17
95
2.17
1.69
3.5
2.4
—
—
—
0
0
5
14
3.83
1.65
2.8
1.9
—
—
—
0
0
5
14
3.83
1.65
4.0
1.9
—
—
—
0
0
6
21
3.09
1.55
14.8
36.9
15.17
17.19
%
—
6
21
27
190
1.88
1.37
3.3
3.3
—
—
estimate
—
0
0
33
251
1.86
1.28
7.5
3.5
0.00
0.00
estimate
-0.00
15
49
33
252
1.85
1.26
7.7
3.6
0.00
0.00
estimate
-0.00
16
50
33
253
1.83
1.23
7.6
3.6
0.00
0.06
estimate
0.49
14
47
0
33
0.00
1.21
0.0
1.6
—
1002.57
—
0
27
5
20
2.65
1.18
1.8
1.8
—
—
—
0
0
5
100
0.45
1.03
1.4
2.6
—
—
—
0
0
26
196
1.65
0.95
7.3
3.3
0.00
0.05
estimate
0.49
14
40
14
90
1.76
0.90
1.9
1.7
—
—
—
0
0
6
32
1.99
0.85
1.2
1.0
—
—
—
0
0
5
92
0.50
0.76
1.2
2.5
—
—
—
0
0
9
58
1.67
0.75
2.6
2.9
6.44
4.82
umol/l
—
9
52
14
97
1.61
0.68
1.3
1.4
7.99
2.64
u/ml
—
7
46
0
22
0.00
0.61
0.0
1.4
—
1.36
—
0
14
0
22
0.00
0.61
0.0
1.4
—
1.23
—
0
14
0
22
0.00
0.61
0.0
1.4
—
0.97
—
0
14
7
48
1.53
0.49
24.0
6.8
—
—
—
0
0
19
152
1.39
0.46
7.7
2.9
0.00
0.00
estimate
-0.00
14
38
9
120
0.70
0.41
1.3
1.7
—
—
—
0
0
39
356
1.38
0.38
3.7
3.7
—
—
—
0
0
12
91
1.41
0.38
5.6
4.9
0.97
1.88
ug/l
1.47
12
82
13
104
1.33
0.30
1.6
1.4
28.12
29.00
iu/ml
—
5
24
5
42
1.21
0.22
1.8
2.2
27.00
26.44
u/l
—
5
36
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
7.3
—
0.00
—
0
6
0
7
0.00
0.00
0.0
1.6
—
66.25
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
48.62
—
0
5
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
364.40
—
0
5
0
5
0.00
-0.00
0.0
1.6
—
70.40
—
0
5
0
5
0.00
-0.00
0.0
8.6
—
8.94
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_AUTOPOLYFAI and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_AUTOPOLYFAI.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_AUTOPOLYFAI – Autoimmune polyglandular failure
GWS hits: 3
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data